Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript May 7, 2024 Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-2.35058 EPS, expectations were $-2.12. Rhythm Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]
While conventional wisdom calls for selling securities, these best Nasdaq stocks may require a complete rethink. With the possibility that the Federal Reserve might get its soft landing after all, risk-on sentiment has returned on Wall Street. Previously, the combination of consistently robust jobs reports and soaring energy prices meant that the central bank would likely have been forced to shift its policy. Rather than cutting interest rates, the Fed appeared to be on course to raise them. How
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -0.43% and 5.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?